Thu Sep 12, 2024 3:43 pm
2024-Ager et al-preprint
"Neoadjuvant androgen deprivation therapy with or without Fc-enhanced non-fucosylated anti-CTLA-4 (BMS-986218) in high risk localized prostate cancer: a randomized phase 1 trial"
Casey R Ager, Aleksandar Obradovic, Patrick McCann, Matthew Chaimowitz, Alexander L.E. Wang, Neha Shaikh, Parin Shah, Samuel Pan, Caroline J Laplaca, Renu K Virk, Jessica C Hill, Collin Jugler, Grace DeFranco, Nilika Bhattacharya, Howard I Scher, Guarionex Joel Decastro, Christopher B Anderson, James M McKiernan, Catherine S Spina, Mark N Stein, Karie Runcie, Charles G Drake, Andrea Califano, Matthew C Dallos
medRxiv, posted September 11, 2024
https://doi.org/10.1101/2024.09.09.24313308
- will update when/if this is peer-reviewed and published
- no dataset accession given
Casey R Ager, Aleksandar Obradovic, Patrick McCann, Matthew Chaimowitz, Alexander L.E. Wang, Neha Shaikh, Parin Shah, Samuel Pan, Caroline J Laplaca, Renu K Virk, Jessica C Hill, Collin Jugler, Grace DeFranco, Nilika Bhattacharya, Howard I Scher, Guarionex Joel Decastro, Christopher B Anderson, James M McKiernan, Catherine S Spina, Mark N Stein, Karie Runcie, Charles G Drake, Andrea Califano, Matthew C Dallos
medRxiv, posted September 11, 2024
https://doi.org/10.1101/2024.09.09.24313308
- will update when/if this is peer-reviewed and published
- no dataset accession given